NYSE American - Delayed Quote USD

iBio, Inc. (IBIO)

1.7200 -0.0500 (-2.82%)
At close: April 19 at 4:00 PM EDT
1.7300 +0.01 (+0.58%)
After hours: April 19 at 7:49 PM EDT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Dr. Martin B. Brenner D.V.M., Ph.D. CEO & Chief Scientific Officer 577.31k -- 1971
Mr. Felipe Duran Chief Financial Officer 1.07M -- 1980
Stephen Kilmer Investor Relations Officer -- -- --
Mr. Marc Banjak J.D. General Counsel -- -- --
Mr. Robert B. Kay Interim Secretary & Interim Treasurer 92.69k -- 1940

iBio, Inc.

8800 Health Science Center Parkway
Bryan, TX 77807-1107
United States
302 355 0650 https://www.ibioinc.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
26

Description

iBio, Inc., a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel. The company is also developing vaccine candidates, including IBIO-101, an antibody to reduce tumor growth; Endostatin E4 peptide for use in chemotherapy and immunotherapy; Trop-2 for the treatment Trop-2 positive cancers; MUC16, a tumor-associated epitope; anti-EGFRvIII antibody to treat glioblastoma and other cancers; CCR8 protein candidate for treatment of various cancers; PD-1 agonist for the treatment of rheumatoid arthritis and other inflammatory diseases; and IBIO-400 for the treatment of classical swine fever. iBio, Inc. has agreement with The Texas A&M University System for designing and manufacturing of plant-made biopharmaceuticals; and a research collaboration with the National Institute of Allergy and Infectious Diseases to investigate the potential of the company's AI-driven epitope steering platform for the development of a vaccine for Lassa fever. The company was incorporated in 2008 and is headquartered in Bryan, Texas.

Corporate Governance

iBio, Inc.’s ISS Governance QualityScore as of April 1, 2024 is 8. The pillar scores are Audit: 10; Board: 6; Shareholder Rights: 4; Compensation: 9.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

May 13, 2024 - May 17, 2024
iBio, Inc. Earnings Call

Related Tickers

AVTX Avalo Therapeutics, Inc.
11.63
-3.16%
 
TNXP Tonix Pharmaceuticals Holding Corp.
0.1600
+1.91%
 
VXRT Vaxart, Inc.
0.7556
-10.29%
 
PALI Palisade Bio, Inc.
4.7100
-7.10%
 
ADIL Adial Pharmaceuticals, Inc.
1.9300
-11.06%
 
PXMD PaxMedica, Inc.
0.7609
-0.29%
 
JAGX Jaguar Health, Inc.
0.1569
-11.41%
 
RLYB Rallybio Corporation
1.7600
+5.39%
 
LGVN Longeveron Inc.
1.9200
-4.48%
 
CADL Candel Therapeutics, Inc.
5.17
-5.31%